ALNYLAM PHARMACEUTICALS, INC. (ALNY) Gross profit 2017–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual gross profit history from SEC filings — each fiscal year as reported.
$3.0BFY2025 · since FY2017: $89.9M → $3.0B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.0B | +56.4% |
| FY2024 | $1.9B | +24.5% |
| FY2023 | $1.6B | +73.9% |
| FY2022 | $897.2M | +23.0% |
| FY2021 | $729.3M | +74.2% |
| FY2020 | $418.7M | +115.0% |
| FY2019 | $194.7M | +166.3% |
| FY2018 | $73.1M | -18.7% |
| FY2017 | $89.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Net marginALNY Gross marginALNY Operating incomeALNY Operating marginALNY Operating cash flowALNY Free cash flowALNY Capital expendituresALNY Return on equityALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Total liabilitiesALNY Shareholders’ equityALNY overview →